Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

NCT02925416 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Skin Diseases, Bacterial

Interventions

DRUG: Oritavancin
DRUG: Placebo (D5W)

Sponsor

The Medicines Company